Smallpox vaccination: Risk considerations for patients with atopic dermatitis

被引:109
作者
Engler, RJM
Kenner, J
Leung, DYM
机构
[1] Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy & Immunol, Denver, CO 80206 USA
[2] Walter Reed Army Med Ctr, Allergy Immunol Dept, Washington, DC 20307 USA
[3] Dept Vet Affairs, Tripler Army Med Ctr, Dermatol Serv, Honolulu, HI USA
[4] Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA
关键词
atopic dermatitis; eczema; smallpox; vaccinia; T cells;
D O I
10.1067/mai.2002.128052
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
As the threat of bioterrorism with pathogenic microbes such as smallpox virus (Variola major) increases, the question of widespread voluntary vaccination with smallpox (vaccinia) vaccines is being carefully considered. A major challenge lies in the ability to protect the population from the disease while minimizing the considerable side effects from the vaccine. Individuals with active or quiescent atopic dermatitis are at increased risk for vaccinia complications. The nature of these complications and other considerations are summarized in this rostrum.
引用
收藏
页码:357 / 365
页数:9
相关论文
共 72 条
[1]   The last smallpox epidemic in Boston and the vaccination controversy, 1901-1903 [J].
Albert, MR ;
Ostheimer, KG ;
Breman, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :375-379
[2]   Viral mechanisms of immune evasion [J].
Alcami, A ;
Koszinowski, UH .
TRENDS IN MICROBIOLOGY, 2000, 8 (09) :410-418
[3]   Perforin hyperreleasability and depletion in cytotoxic T cells from patients with exacerbated atopic dermatitis and asymptomatic rhinoconjunctivitis allergica [J].
Ambach, A ;
Bonnekoh, B ;
Gollnick, H .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (05) :878-886
[4]  
[Anonymous], 2001, MMWR-MORBID MORTAL W, V50, P1
[5]  
[Anonymous], 1998, TXB DERMATOPATHOLOGY
[6]  
[Anonymous], ACTA DERM VENERE S92, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]
[7]   Atopic dermatitis is associated with a low-producer transforming growth factor β1 cytokine genotype [J].
Arkwright, PD ;
Chase, JM ;
Babbage, S ;
Pravica, V ;
David, TJ ;
Hutchinson, IV .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 108 (02) :281-+
[8]   Human α-defensin 1 (HNP-1) inhibits adenoviral infection in vitro [J].
Bastian, A ;
Schäfer, H .
REGULATORY PEPTIDES, 2001, 101 (1-3) :157-161
[9]  
Bicknell WJ, 2002, NEW ENGL J MED, V346, P1323, DOI 10.1056/NEJMsb020357
[10]  
BINDER D, 1991, J IMMUNOL, V146, P4301